Pliant Therapeutics

Pliant Therapeutics, Inc. discovers and develops novel therapies for fibrotic diseases.
Pliant Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Pliant Therapeutics balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Pliant Therapeutics cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Pliant Therapeutics multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Pliant Therapeutics profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Pliant Therapeutics assets
Pliant Therapeutics cash flows

Pliant Therapeutics shares

TickerNameTypeNominal valueISINPrice
PLRX:USPliant TherapeuticsCommon share-US7291391057$14.65
Pliant Therapeutics news
10.05.2022
Pliant Therapeutics' GAAP loss for 3 months of 2022 was $28.1 million, up 22.9% from $22.856 million in the prior year. Revenue decreased 42.5% to $1,249 million from $2,174 million a year earlier.
Source: {source} pictogram ir.pliantrx.com
Pictogram next
01.03.2022
Pliant Therapeutics' GAAP loss for 2021 was $97.263 million, up 2.3 times from $41.533 million in the previous year. Revenue decreased 5.3 times to $7.572 million from $41.817 million a year earlier.
Source: {source} pictogram ir.pliantrx.com
Pictogram next
10.11.2021
Pliant Therapeutics' GAAP loss for 9M 2021 was $72.732 million, up 3.2 times from $22.506 million in the previous year. Revenue decreased 6.7-fold to $5.573 million from $37.352 million a year earlier.
Source: {source} pictogram ir.pliantrx.com
Pictogram next
10.08.2021
Pliant Therapeutics' GAAP loss for 6M 2021 was $45.687 million, up 7.65 times from $5.972 million in the previous year. Revenue declined 8.2 times to $3.963 million from $32.538 million a year earlier.
Source: {source} pictogram ir.pliantrx.com
Pictogram next
All Pliant Therapeutics news
General information
Company namePliant Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
Mailing address260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Websitewww.pliantrx.com
Information disclosurewww.sec.gov